Search results
Results from the WOW.Com Content Network
An increase in antiplatelet effect would increase the risk of bleeding and could cause prolonged or excessive bleeding. A decrease in antiplatelet effect would reduce the risk of bleeding, but increase the thromboembolic risk. [3] Drug toxicity may increase when multiple antiplatelet drugs are used.
The biggest risk of anticoagulation therapy is the increased risk of bleeding. [15] In otherwise healthy people, the increased risk of bleeding is minimal, but those who have had recent surgery, cerebral aneurysms , and other conditions may have too great a risk of bleeding.
NSAIDs cause decreased ability to form blood clots, which can increase the risk of bleeding when combined with other drugs that also decrease blood clotting, such as warfarin. [113] NSAIDs may aggravate hypertension (high blood pressure) and thereby antagonize the effect of antihypertensives, [113] such as ACE inhibitors. [114]
In addition to NSAID-related bleeding, another common cause of bleeding is that related to the medication, warfarin ("Coumadin" and others). This medication needs to be closely monitored as the bleeding risk can be markedly increased by interactions with other medications. Warfarin acts by inhibiting the production of Vitamin K in the gut ...
[24] [25] However, conflicting evidence from another review suggested that dabigatran might not substantially increase the risk of heart attacks, or if it does, then the associated risk is relatively low. [26] For patients with moderately reduced kidney function, lower dabigatran doses are recommended due to increased drug exposure and bleeding ...
Increased bleeding risk, especially in the stomach; Gastrointestinal irritation; Used in risk factor control and acute coronary syndrome; Dual antiplatelet therapy with P2Y12 inhibitors for a reduction of risk of major adverse cardiac events for all acute coronary syndrome patients [24]
A number of medications increase the risk of bleeding including NSAIDs and SSRIs. SSRIs double the rate of upper gastrointestinal bleeding. [4] There are many causes for upper gastrointestinal hemorrhage. Causes are usually anatomically divided into their location in the upper gastrointestinal tract. [citation needed]
The limitations of current antiplatelet drugs contain risk of bleeding and interindividual variability of platelet inhibitory response. [6] The aim is to determine the optimal therapeutic window to maximize therapeutic benefits while reducing safety concerns like bleeding. Consequently, the major unmet goal of ADP inhibitors is to develop a ...